Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Friday September 11, 2009
DrStockPick.com Stock Report!
GVBP, GENova Biotherapeutics Inc, GVBP.OB
GVBP’s New stem cell identification technology could cure breast cancer
GVBP is positioning itself as the world’s leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.
GVBP has filed a patent for a potential blockbuster drug target that combats breast cancer.
The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.
This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, leaving healthy cells intact, with no side effects, and no harm to surrounding healthy tissues.
The target, Tetanolic acid has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy
GVBP’s innovative method for destroying breast cancer cells, using stem cell technology, is based on cutting-edge technology that enables us to identify the protein expression in the original cancer stem cells that give rise to tumors. This ability to identify the molecular markers of these cells is an important first step in developing new and superior cancer cures.
GVBP’s biotechnology is tracing cancer cells to their origin, the very stem cells from where the first malignant cell arose. This technology will also enable GVBP to identify healthy stem cells and then develop, inject, and nurture them in such a way that they can overcome the malignant cells. Eventually, healthy stem cells will overcome the sick cells, leaving the patient cured.
This novel method for treating breast cancer has tremendous market potential, is far superior to existing treatments, and is the underpinning of GVBP’s IP (Intellectual Property) portfolio.
More about GVBP at www.genovabio.com
No comments :
Post a Comment